Thursday, March 23, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Turnkey Detection: Rapid Diagnostics in the Field

by Global Biodefense Staff
October 25, 2016
Turnkey Detection: Rapid Diagnostics in the Field

A schematic showing the fluorescent signal obtained from the RNA of the MERS coronavirus using DTRA-developed technology that combines point-ofsampling amplification of the RNA and a signaling beacon made out of redesigned nucleic acid. Figures courtesy of Dr. Steven Benner, FfAME.

Health care providers need an assay that detects the nucleic acids, the DNA or RNA from the pathogen, in both biological and environmental samples at the point of care, offering a flexible “single source” solution. A tool that can detect multiple diseases would be valuable not only in terms of protection, but in terms of affordability. Costing upwards of $200 a test, traditional diagnostic tools are expensive at scale.

In an effort funded by the Defense Threat Reduction Agency’s Joint Science and Technology Office, Dr. Steven Benner from the Foundation for Applied Molecular Evolution (FfAME), is working to developing  developing a turnkey, adaptable and cost-effective device to test for several pathogens in a single assay. The device will not require laboratory diagnostic tools and can be used with minimal training.

Molecular Beacons

As reported in the Journal of Virological Methods article “Standard and AEGIS Nicking Molecular Beacons Detect Amplicons from the Middle East Respiratory Syndrome Coronavirus,” the on-site reporting capability showed the adaptability of the diagnostic tool to detect a coronavirus (CoV) that causes the Middle East Respiratory Syndrome (MERS).

Dr. Benner utilized a previously discovered DTRA-supported tool, the artificially expanded genetic information system (AEGIS), to create the new, high sensitivity diagnostic tool with low noise. AEGIS works by adding nucleotides to the four found in standard DNA and RNA, pairing orthogonally to the A:T and G:C pairs.

Molecular beacons containing AEGIS then generate florescent light signals, detectable at points of sampling, where it can be read on the spot or captured by a cell phone camera for transmission to a remote site for evaluation and epidemiological use. Placing AEGIS components in the stems of molecular beacons lowers noise (thus reducing the ‘signal to noise’ ratio) by preventing unwanted cross-reaction with natural DNA that is abundant in natural environmental and human diagnostic samples.

As a further innovation, the diagnostic kit engineers the beacon so that a single target molecule turns over multiple copies of the beacon, allowing it to amplify the signal, increasing the sensitivity of the assay.

Combining these technologies allows the detection of as few as 50 copies of MERS-CoV RNA in the form of a green glow visible to the human eye, significantly stronger than existing point-of-sampling kits. In addition to detecting MERS, it provides accurate results in detecting influenza A and B, severe acute respiratory syndrome (SARS) and human respiratory syncytial virus (RSV); all viruses easily confused with the symptoms generated by MERS.

Adapted from DTRA Chemical and Biological Technologies Department

Tags: CoronavirusEditor PickMERS-CoVRapid Diagnostics

Related Posts

New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC